CSIMarket
 


Allakos Inc   (ALLK)
Other Ticker:  
 

Allakos Inc 's Leverage Ratio

ALLK's quarterly Leverage Ratio and Total Liabilities, Equity growth




ALLK Leverage Ratio (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Equity Change -34.39 % -60.98 % -57.82 % 7.65 % 17.35 %
Y / Y Total Liabilities Change -22.93 % 0.17 % 26.87 % 234.74 % 251.59 %
Leverage Ratio MRQ 0.22 0.38 0.33 0.2 0.18
Overall Ranking # # # # #
Seq. Equity Change 54.47 % -14.26 % -41.66 % -15.08 % -8.13 %
Seq. Total Liabilities Change -11.55 % -2.1 % -3.85 % -7.44 % 14.96 %



Leverage Ratio third quarter 2022 Comment
Due to repayements of liabilities of -11.55% Allakos Inc improved Leverage Ratio in third quarter 2022 to 0.22, above company's average Leverage Ratio.

Within Major Pharmaceutical Preparations industry Allakos Inc achieved lowest Leverage Ratio. While total ranking remained unchanged compare to previous quarter at no. .

Explain Leverage Ratio?
Who are ALLK Customers?
Leverage Ratio third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #


Leverage Ratio Statistics
High Average Low
0 0 0
 




Financial Statements
Allakos Inc 's Equity $ 344 Millions Visit ALLK's Balance sheet
Allakos Inc 's Total Liabilities $ 74 Millions Visit ALLK's Balance sheet
Source of ALLK's Sales Visit ALLK's Sales by Geography


Cumulative Allakos Inc 's Leverage Ratio

ALLK's Leverage Ratio for the trailling 12 Months

ALLK Leverage Ratio

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Equity TTM Growth -34.39 % -60.98 % -57.82 % 7.65 % 17.35 %
Y / Y Total Liabilities TTM Growth -22.93 % 0.17 % 26.87 % 234.74 % 251.59 %
Leverage Ratio TTM 0.26 0.24 0.2 0.16 0.13
Total Ranking TTM # 250 # 592 # 510 # 169 # 637
Seq. Equity TTM Growth 54.47 % -14.26 % -41.66 % -15.08 % -8.13 %
Seq. Total Liabilities TTM Growth -11.55 % -2.1 % -3.85 % -7.44 % 14.96 %


TTM Leverage Ratio Comment
On the trailing twelve months basis Despite of the repayements of liabilities of -11.55% in III. Quarter, Leverage Ratio improved to 0.26, a new company high.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 83 other companies have achieved lower Leverage Ratio than Allakos Inc . While total ranking remained unchanged compare to previous quarter at no. 250.

Explain Leverage Ratio?
Who are ALLK Customers?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 84
Healthcare Sector # 149
Within the Market # 250


TTM Leverage Ratio Statistics
High Average Low
0.26 0.12 0.05
(Sep 30 2022)   (Jun 30 2020)




Companies with similar Leverage Ratio in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Leverage RatioSep 30 2022 MRQ Total LiabilitiesSep 30 2022 MRQ Equity
Pds Biotechnology Corp  0.59 $ 27.828  Millions$ 47.059  Millions
Kiora Pharmaceuticals inc   0.59 $ 6.203  Millions$ 10.521  Millions
Applied Molecular Transport Inc   0.59 $ 46.212  Millions$ 78.395  Millions
Macrogenics Inc   0.59 $ 72.389  Millions$ 122.958  Millions
Acelrx Pharmaceuticals Inc  0.57 $ 15.432  Millions$ 27.226  Millions
Iterum Therapeutics Plc  0.56 $ 18.089  Millions$ 32.549  Millions
Marizyme Inc   0.55 $ 22.357  Millions$ 40.948  Millions
Medavail Holdings Inc   0.54 $ 16.807  Millions$ 31.306  Millions
Scpharmaceuticals Inc   0.53 $ 16.582  Millions$ 31.110  Millions
Vaxxinity Inc   0.53 $ 42.699  Millions$ 80.261  Millions
Aptinyx Inc   0.52 $ 25.193  Millions$ 48.792  Millions
Cyclerion Therapeutics Inc   0.52 $ 8.529  Millions$ 16.524  Millions
Aditxt Inc   0.51 $ 6.485  Millions$ 12.694  Millions
Cue Biopharma Inc   0.50 $ 25.536  Millions$ 50.764  Millions
Uniqure N v   0.50 $ 210.630  Millions$ 421.170  Millions
Cellectar Biosciences Inc   0.50 $ 6.367  Millions$ 12.751  Millions
Eyenovia inc   0.48 $ 9.692  Millions$ 20.329  Millions
Decibel Therapeutics Inc   0.47 $ 45.459  Millions$ 96.814  Millions
Metacrine Inc   0.46 $ 17.109  Millions$ 37.065  Millions
F star Therapeutics Inc   0.46 $ 25.953  Millions$ 56.938  Millions
Transcode Therapeutics Inc   0.45 $ 3.748  Millions$ 8.244  Millions
Beigene Ltd   0.44 $ 2,070.842  Millions$ 4,655.171  Millions
Amphastar Pharmaceuticals Inc   0.44 $ 221.530  Millions$ 505.165  Millions
Adial Pharmaceuticals Inc   0.43 $ 2.333  Millions$ 5.409  Millions
Nighthawk Biosciences inc   0.43 $ 35.699  Millions$ 83.126  Millions
Integrated Biopharma Inc  0.42 $ 7.743  Millions$ 18.621  Millions
Acadia Pharmaceuticals Inc   0.42 $ 176.805  Millions$ 425.686  Millions
Theriva Biologics inc   0.41 $ 22.552  Millions$ 55.415  Millions
Cyclacel Pharmaceuticals Inc   0.41 $ 8.954  Millions$ 22.067  Millions
Calithera Biosciences Inc   0.41 $ 10.695  Millions$ 26.388  Millions

Date modified: 2022-11-08T18:10:25+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

GNRS's Profile

Stock Price

GNRS's Financials

Business Description

Fundamentals

Charts & Quotes

GNRS's News

Suppliers

GNRS's Competitors

Customers & Markets

Economic Indicators

GNRS's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071